Boston Scientific Corp. manufactures, markets, and develops medical devices for use in interventional medicine, and seven business areas are under the company’s control: Urology and Pelvic Health, Cardiac Rhythm Management, Interventional Cardiology, Peripheral Interventions, Endoscopy, Neuromodulation, and Electrophysiology. It operates in three segments: Rhythm and Neuro, Cardiovascular and MedSurg.
In the Rhythm and Neuro segment, implantable electronic devices are developed to monitor the heart and to deliver electric current to treat anomalies in the heart. The Cardiovascular segment comprises of technologies used in diagnosing and treating coronary artery disease and other cardiovascular disorders including structural heart conditions.
As part of its MedSurg segment, the company offers innovative tools for diagnosing and treating a variety of conditions pertaining to the gastrointestinal tract and the lungs. Products in the Interventional Cardiology arena include balloon catheters, rotational atherectomy systems, guide wires, guide catheters, embolic protection devices, as well as diagnostic catheters used during percutaneous transluminal coronary angioplasty procedures (PTCA). One of the most successful products developed by Boston Scientific is the Taxus Stent, which is a drug-eluting stent commonly used to open clogged arteries. Upon acquisitioning Cameron Health in June 2012, the company also became notable for offering a subcutaneous implantable cardioverter-defibrillator (ICD) which they named the EMBLEM Subcutaneous Implantable Defibrillator (S-ICD). Boston Scientific offers a wide range of products that contribute to the advancement of less-invasive medicine. The use of these less invasive medical technologies offers an alternative to major surgery and other processes that are often traumatic to the human body. These procedures often involve the insertion of devices through natural openings or small incisions; these devices can be guided into most parts of the anatomy in order to diagnose and treat a wide array of medical problems.
By combining the effectiveness of transurethral resection of the prostate (TURP), with fewer risks and side effects, GreenLight XPS™ Laser Therapy is one of the most effective minimally invasive treatments available today. Benign Prostate Hyperplasia (BPH) can be effectively treated with GreenLight’s laser system. Greenlight XPS™ has the same safety profile as HPS and PV systems for laser applications up to 180 watts.
Most patients with an enlarged prostate can benefit from GreenLight XPS™ Laser Therapy. Patients suffering from Benign Prostatic Hyperplasia (BPH) can now receive the most advanced standard of care from GreenLight, which offers patients freedom from symptoms associated with enlarged prostates.
Vercise™ DBS System
The Vercise DBS system is the first system designed to target the neural mechanisms specifically to patients with Parkinson’s disease, primary and secondary dystonia, as well as essential tremor. There are many benefits to rechargeable systems, including longer battery life and shorter footprint than other types of multiple-source stimulation systems.
August 3, 2021